Results 131 to 140 of about 14,759,288 (215)

Opioid use disorder in custodial settings: Continuity of opioid agonist therapy at a critical clinical inflection point. [PDF]

Can Fam Physician
Albert OM, Arthur A, Beshara F.
europepmc   +1 more source

Depression in Opioid Use Disorder: A Tripartite Psychopathological Model for Dual Disorders. [PDF]

J Clin Med
Maremmani AGI, Della Rocca F, Bacciardi S, Cimino S, Cerniglia L, Pallucchini A, Carbone MG, Miccoli M, Maremmani I.   +8 more
europepmc   +1 more source

The evolving epidemiology of opioid use disorder: polysubstance use, drug supply transformation, and policy implications. [PDF]

Front Public Health
Mandapati NK, Tovar DC, Bindlish R, Hernandez YL, Alves MJ, Baum MK, Aggarwal S.   +6 more
europepmc   +1 more source

Optimal buprenorphine exposure to treat patients with opioid use disorder in the era of fentanyl and polysubstance use. [PDF]

Front Pharmacol
Lohmer LRL, Greenwald MK, Kakar R, Laffont CM.   +3 more
europepmc   +1 more source

Characterizing the Relationship Between Nonmedical Use of Gabapentin and Gabapentin Prescribing Among Individuals With Opioid Use Disorder. [PDF]

J Addict Med
Ellis MS, Sharma R, Ayres K, Stone JW, Buttram ME.   +4 more
europepmc   +1 more source

Non-pharmacological interventions for opioid use disorder: protocol for a systematic review and network meta-analysis. [PDF]

Front Public Health
Li M, Miao D, Mo Q, Chen Q, Lu L.
europepmc   +1 more source

Telemedicine and increased retention in medications for opioid use disorder treatment. [PDF]

Addict Sci Clin Pract
Smith AJ, Witcraft SM, Lane S, Guille C.
europepmc   +1 more source

Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. [PDF]

Oncologist
Segar J, Farr K, Junak M, Roe D, Ehsani S, Ibrahim M, Vanderah TW, Chalasani P.   +7 more
europepmc   +1 more source